Anaplastic thyroid carcinoma: a nationwide cohort study on incidence, treatment and survival in the Netherlands over 3 decades

in European Journal of Endocrinology

Correspondence should be addressed to M de Ridder; Email: M.de_Ridder.RT@lumc.nl
Restricted access

Objective

To perform a nationwide population based study in ATC on incidence, treatment and survival.

Design

Retrospective cohort study.

Methods

All patients with primary ATC between 1989 and 2016 were identified in the Netherlands Cancer Registry (NCR). Of all these patients excerpts from the pathology reports from PALGA: Dutch Pathology registry were linked to the data of the NCR. Standardized incidences were calculated, survival was estimated using Kaplan–Meier method and univariable statistically significant factors were included in a multivariable regression model.

Results

In total, 812 patients were included. Mean standardized incidence rates were 0.18/100 000 (range 0.11–0.27/100 000) with a significant trend over the years with an estimated annual percentage change of 1.3% per year (95% CI 0.4–2.1%). Median overall survival was 2.2 months, and estimated 1-year survival was 12%. Patients without distant metastases at diagnosis had an estimated 1-year survival of 21.6%. Prognostic factors for prolonged survival were double or triple therapy, age below 65 years, M0-status and absence of bilateral lymph node metastases.

Conclusions

ATC is rare, but often lethal, form of thyroid cancer, with a median survival of 2 months and 1-year survival of approximately 10%. The incidence is slightly rising in the Netherlands over the past 3 decades. There appears to be a subgroup of patients that survive longer, mainly those with relatively limited disease who underwent double or triple therapy. Further research is needed to define these patients more distinctively.

 

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 717 717 406
Full Text Views 82 82 52
PDF Downloads 47 47 25
  • 1

    KebebewEGreenspanFSClarkOHWoeberKAMcMillanA. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005 103 13301335. (https://doi.org/10.1002/cncr.20936)

    • Search Google Scholar
    • Export Citation
  • 2

    RaoSNZafereoMDaduRBusaidyNLHessKCoteGJWilliamsMDWilliamWNSandulacheVGrossN Patterns of treatment failure in anaplastic thyroid carcinoma. Thyroid 2017 27 672681. (https://doi.org/10.1089/thy.2016.0395)

    • Search Google Scholar
    • Export Citation
  • 3

    AreCShahaAR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Annals of Surgical Oncology 2006 13 453464. (https://doi.org/10.1245/ASO.2006.05.042)

    • Search Google Scholar
    • Export Citation
  • 4

    Aschebrook-KilfoyBWardMHSabraMMDevesaSS. Thyroid cancer incidence patterns in the United States by histologic type, 1992–2006. Thyroid 2011 21 125134. (https://doi.org/10.1089/thy.2010.0021)

    • Search Google Scholar
    • Export Citation
  • 5

    SmallridgeRCAinKBAsaSLBibleKCBrierleyJDBurmanKDKebebewELeeNYNikiforovYERosenthalMS American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2012 22 11041139. (https://doi.org/10.1089/thy.2012.0302)

    • Search Google Scholar
    • Export Citation
  • 6

    HaddadRILydiattWMBallDWBusaidyNLByrdDCallenderGDicksonPDuhQYEhyaHHaymartM et al. Anaplastic thyroid carcinoma, version 2.2015. Journal of the National Comprehensive Cancer Network 2015 13 11401150. (https://doi.org/10.6004/jnccn.2015.0139)

    • Search Google Scholar
    • Export Citation
  • 7

    WuHSunYYeHYangSLeeSLde las MorenasA. Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets. Pathology Oncology Research 2015 21 695701. (https://doi.org/10.1007/s12253-014-9876-5)

    • Search Google Scholar
    • Export Citation
  • 8

    PezziTAMohamedASRSheuTBlanchardPSandulacheVCLaiSYCabanillasMEWilliamsMDPezziCMLuC Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: outcomes from the National Cancer Data Base. Cancer 2017 123 16531661. (https://doi.org/10.1002/cncr.30493)

    • Search Google Scholar
    • Export Citation
  • 9

    Swaak-KragtenATde WiltJHSchmitzPIBontenbalMLevendagPC. Multimodality treatment for anaplastic thyroid carcinoma – treatment outcome in 75 patients. Radiotherapy and Oncology 2009 92 100104. (https://doi.org/10.1016/j.radonc.2009.02.016)

    • Search Google Scholar
    • Export Citation
  • 10

    WendlerJKroissMGastKKreisslMCAlleleinSLichtenauerUBlaserRSpitzwegCFassnachtMSchottM Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. European Journal of Endocrinology 2016 175 521529. (https://doi.org/10.1530/EJE-16-0574)

    • Search Google Scholar
    • Export Citation
  • 11

    van der SandenGACoeberghJWSchoutenLJVisserOvan LeeuwenFE. Cancer incidence in the Netherlands in 1989 and 1990: first results of the nationwide Netherlands cancer registry. Coordinating Committee for Regional Cancer Registries. European Journal of Cancer 1995 31A 18221829. (https://doi.org/10.1016/0959-8049(95)00355-m)

    • Search Google Scholar
    • Export Citation
  • 12

    FritzA. International Classification of Disease for Oncology. Geneva: World Health Organization2000.

  • 13

    LimHDevesaSSSosaJACheckDKitaharaCM. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA 2017 317 13381348. (https://doi.org/10.1001/jama.2017.2719)

    • Search Google Scholar
    • Export Citation
  • 14

    OlsonEWintheiserGWolfeKMDroesslerJSilbersteinPT. Epidemiology of thyroid cancer: a review of the National Cancer Database, 2000–2013. Cureus 2019 11 e4127. (https://doi.org/10.7759/cureus.4127)

    • Search Google Scholar
    • Export Citation
  • 15

    JanzTANeskeyDMNguyenSALentschEJ. Is the incidence of anaplastic thyroid cancer increasing: a population based epidemiology study. World Journal of Otorhinolaryngology: Head and Neck Surgery 2019 5 3440. (https://doi.org/10.1016/j.wjorl.2018.05.006)

    • Search Google Scholar
    • Export Citation
  • 16

    DemeterJGDe JongSALawrenceAMPaloyanE. Anaplastic thyroid carcinoma: risk factors and outcome. Surgery 1991 110 956961; discussion 6163.

    • Search Google Scholar
    • Export Citation
  • 17

    https://www.palgaopenbaredatabank.nl/menu/main/dataexplorer?entity=PalgaSample&hideselect=true. Accessed on 10 July 2019.

  • 18

    BaekSKLeeMCHahJHAhnSHSonYIRhoYSChungPSLeeYSKooBSJungKY Role of surgery in the management of anaplastic thyroid carcinoma: Korean nationwide multicenter study of 329 patients with anaplastic thyroid carcinoma, 2000 to 2012. Head and Neck 2017 39 133139. (https://doi.org/10.1002/hed.24559)

    • Search Google Scholar
    • Export Citation
  • 19

    SugitaniIMiyauchiASuginoKOkamotoTYoshidaASuzukiS. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World Journal of Surgery 2012 36 12471254. (https://doi.org/10.1007/s00268-012-1437-z)

    • Search Google Scholar
    • Export Citation
  • 20

    HuangNSShiXLeiBWWeiWJLuZWYuPCWangYJiQHWangYL. An update of the appropriate treatment strategies in anaplastic thyroid cancer: a population-based study of 735 patients. International Journal of Endocrinology 2019 2019 8428547. (https://doi.org/10.1155/2019/8428547)

    • Search Google Scholar
    • Export Citation
  • 21

    KasaianKWisemanSMWalkerBAScheinJEZhaoYHirstMMooreRAMungallAJMarraMAJonesSJM. The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy. BMC Cancer 2015 15 984. (https://doi.org/10.1186/s12885-015-1955-9)

    • Search Google Scholar
    • Export Citation
  • 22

    WeinbergerPPonnySRXuHBaiSSmallridgeRCoplandJSharmaA. Cell cycle M-phase genes are highly upregulated in anaplastic thyroid carcinoma. Thyroid 2017 27 236252. (https://doi.org/10.1089/thy.2016.0285)

    • Search Google Scholar
    • Export Citation
  • 23

    SubbiahVKreitmanRJWainbergZAChoJYSchellensJHMSoriaJCWenPYZielinskiCCabanillasMEUrbanowitzG Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. Journal of Clinical Oncology 2018 36 713. (https://doi.org/10.1200/JCO.2017.73.6785)

    • Search Google Scholar
    • Export Citation